Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 118
Special Issue Editors
Interests: regenerative medicine; mesenchymal stromal cells; osteoarthritis; extracellular vesicles; miRNA
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mesenchymal stromal cells (MSCs) have gained attention in the field of regenerative medicine. MSCs’ differentiation potential, together with their paracrine properties, has made them a crucial option for tissue healing and repair. MSCs’ paracrine properties rely on the release of soluble factors and extracellular vesicles (EVs) such as exosomes and microvesicles. EVs’ origin is mainly endosomal, and they shuttle a cargo defined by several active molecules such as miRNA, mRNA, lipids and proteins that are transferred from their original cells to target cells. In the last decade, EVs have been postulated as crucial players for the therapeutic effect of MSCs in several in vitro and in vivo disease models. Moreover, a number of clinical trials using MSC-EVs have been started, covering cancer, neurological diseases, diabetes and COVID-19. Hence, MSC-EVs may be envisioned as a cell-free therapy in regenerative medicine and all those diseases where tissue healing is needed. Nevertheless, a thorough characterization of the cargo fingerprint associated with the MSC source and an explanation of MSCs’ properties are still largely missing. Therefore, the aim of this Special Issue is to collect reports from in vitro studies to clinical trials, thereby shedding light on MSC-EV features at both the physiological and molecular levels.
Dr. Enrico Ragni
Dr. Daniela Boselli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesenchymal stromal cells
- extracellular vesicles
- regenerative medicine
- miRNA
- lipids
- cytokines
